` TCBP (TC BioPharm Ltd) vs S&P 500 Comparison - Alpha Spread

T
TCBP
vs
S&P 500

Over the past 12 months, TCBP has underperformed S&P 500, delivering a return of -95% compared to the S&P 500's +14% growth.

Stocks Performance
TCBP vs S&P 500

Loading
TCBP
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
TCBP vs S&P 500

Loading
TCBP
S&P 500
Difference
www.alphaspread.com

Performance By Year
TCBP vs S&P 500

Loading
TCBP
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
TC BioPharm Ltd vs Peers

S&P 500
TCBP
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

TC BioPharm Ltd
Glance View

Market Cap
63k USD
Industry
Biotechnology

TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel immunotherapy products based on its proprietary allogeneic gamma delta T cell platform. The firm is engaged in developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease. The firm's platform technology allows Company's to design specific therapies to treat a range of cancers and infectious diseases with off the shelf allogeneic gamma delta T cell (GDT) products. The Company’s pipeline includes OmnImmune, ImmuniStim and CAR-T programs. OmnImmune is an unmodified allogeneic gamma delta T cell product, being used for the treatment of acute myeloid leukemia (AML). ImmuniStim is an unmodified allogeneic gamma delta T cell product, being used for the treatment of COVID-19. The firm also provides in-house and partner programs at the pre-clinical stage focused on developing CAR modified allogeneic gamma delta T-cell products targeting solid and hematological indications.

TCBP Intrinsic Value
Not Available
T
Back to Top